9783764317508 - non-steroidal anti-inflammatory drugs basis for variability in response: 16–18 may, 1985, at leura, new south wales, australia: 17 (agents and actions supplements) de brooks; day (10 resultados)
- Tapa blanda
Librería: Ammareal, Morangis, FranciaAmmareal
Contactar con el vendedorVendedor de 5 estrellasCondición: Usado - Muy bueno
EUR 3,50
Envío por EUR 16,50Se envía de Francia a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Softcover. Condición: Bon. Ancien livre de bibliothèque avec équipements. Edition 1985. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Good. Former library book. Edition 1985. Ammareal gives back up to 15% of this item's net price to charity orga…nizations.
- Tapa blanda
Librería: Ria Christie Collections, Uxbridge, Reino UnidoRia Christie Collections
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 60,72
Envío por EUR 13,90Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New. In.
- Tapa blanda
Librería: Chiron Media, Wallingford, Reino UnidoChiron Media
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 56,99
Envío por EUR 17,98Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 10 disponibles
PF. Condición: New.
- Tapa blanda
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 69,24
Envío por EUR 10,50Se envía de Irlanda a Estados Unidos de AmericaCantidad disponible: 15 disponibles
Condición: New. Series: Agents and Actions, Supplements. Num Pages: 203 pages, 8 black & white illustrations, biography. BIC Classification: YQS. Category: (G) General (US: Trade). Dimension: 244 x 170 x 11. Weight in Grams: 545. . 1985. Softcover reprint of the original 1st ed. 1985. Paperback. . . . .
- Tapa blanda
Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 79,34
Envío por EUR 14,51Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Paperback. Condición: Brand New. 208 pages. German language. 9.61x6.70x0.44 inches. In Stock.
- Tapa blanda
Librería: Kennys Bookstore, Olney, MD, Estados Unidos de AmericaKennys Bookstore
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 87,08
Envío por EUR 9,19Se envía dentro de Estados Unidos de AmericaCantidad disponible: 15 disponibles
Condición: New. Series: Agents and Actions, Supplements. Num Pages: 203 pages, 8 black & white illustrations, biography. BIC Classification: YQS. Category: (G) General (US: Trade). Dimension: 244 x 170 x 11. Weight in Grams: 545. . 1985. Softcover reprint of the original 1st ed. 1985. Paperback. . . . . Books ship from the US an…d Ireland.
- Tapa blanda
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 53,49
Envío por EUR 61,85Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs in the community. This reflects the high frequency of rheumatic complaints but may in part be due to the relative non efficacy of these drugs. Si…nce the introduction of ibuprofen, the first new NSAID to compete with aspirin, phenylbutazone and indomethacin, there has been a proliferation of new NSAIDs of differing chemical classes but an apparent similar spectrum of action. Despite the fact that these drugs are thought to work by an apparent common mechanism of action (suppression of prostaglandin synthetase activity) continued development of these drugs occurs. There exists at present a conflict between the pharmaceutical industry with its attempts to introduce new NSAIDs and drug regulatory authorities who are generally not convinced of the need for additional drugs of_ this class. The practising clinician regards a variety of NSAIDs as necessary to enable pain relief to be optimised.with minimal adverse effects. With respect to the dilemma of how many NSAIDs are really necessary surprisingly little convincing data is available to assist in resolving this issue. It was therefore decided to hold a satellite meeting to the XVIth International League Against Rheumatism Conference in May 1985.
- Tapa blanda
- Impresión bajo demanda
Librería: moluna, Greven, Alemaniamoluna
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 48,37
Envío por EUR 48,99Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Kartoniert / Broschiert. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs in the community. This reflects the high frequency of rheumatic complaints but may in par…t be due to the relative non efficacy of these drugs. Since the i.
Idioma: Inglés
Editorial: Springer, Basel, Birkhäuser Basel, Birkhäuser Jan 1985, 1985
- Tapa blanda
- Impresión bajo demanda
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AlemaniaBuchWeltWeit Ludwig Meier e.K.
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 85,59
Envío por EUR 23,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs in the community. This reflects the high frequency of rheumatic complaints but may in part be due to the relative non efficacy of… these drugs. Since the introduction of ibuprofen, the first new NSAID to compete with aspirin, phenylbutazone and indomethacin, there has been a proliferation of new NSAIDs of differing chemical classes but an apparent similar spectrum of action. Despite the fact that these drugs are thought to work by an apparent common mechanism of action (suppression of prostaglandin synthetase activity) continued development of these drugs occurs. There exists at present a conflict between the pharmaceutical industry with its attempts to introduce new NSAIDs and drug regulatory authorities who are generally not convinced of the need for additional drugs of_ this class. The practising clinician regards a variety of NSAIDs as necessary to enable pain relief to be optimised.with minimal adverse effects. With respect to the dilemma of how many NSAIDs are really necessary surprisingly little convincing data is available to assist in resolving this issue. It was therefore decided to hold a satellite meeting to the XVIth International League Against Rheumatism Conference in May 1985. 203 pp. Englisch.
- Tapa blanda
- Impresión bajo demanda
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemaniabuchversandmimpf2000
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 53,49
Envío por EUR 60,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs in the community. This reflects the high frequency of rheumatic complaints but may in part be due to the relative non efficacy of the…se drugs. Since the introduction of ibuprofen, the first new NSAID to compete with aspirin, phenylbutazone and indomethacin, there has been a proliferation of new NSAIDs of differing chemical classes but an apparent similar spectrum of action. Despite the fact that these drugs are thought to work by an apparent common mechanism of action (suppression of prostaglandin synthetase activity) continued development of these drugs occurs. There exists at present a conflict between the pharmaceutical industry with its attempts to introduce new NSAIDs and drug regulatory authorities who are generally not convinced of the need for additional drugs of_ this class. The practising clinician regards a variety of NSAIDs as necessary to enable pain relief to be optimised.with minimal adverse effects. With respect to the dilemma of how many NSAIDs are really necessary surprisingly little convincing data is available to assist in resolving this issue. It was therefore decided to hold a satellite meeting to the XVIth International League Against Rheumatism Conference in May 1985.Springer Nature c/o IBS, Benzstrasse 21, 48619 Heek 208 pp. Englisch.
